Trial reportNeurology2014
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Trial report in Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.JAMA neurology · 2017Trial
- ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.BMC neurology · 2016Trial
- Personalised Anti-CD20 Retreatment in Multiple Sclerosis: Precision Medicine or Precision Pharmacology?European journal of neurology · 2026Article
- Alemtuzumab for haematological malignancies.Annals of hematology · 2025Review
- Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.European thyroid journal · 2024Article
- Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.Journal of neuroinflammation · 2023Article
- Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence.Journal of clinical medicine · 2023Article
- Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.Frontiers in immunology · 2023Article
- Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.Brain : a journal of neurology · 2022Article
- Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Antibody-mediated cell depletion therapies in multiple sclerosis.Frontiers in immunology · 2022Review
- Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.Frontiers in immunology · 2021Article
- Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Article
- Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.Multiple sclerosis and related disorders · 2020Review
- Detecting and predicting neutralization of alemtuzumab responses in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Review
- Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy.BMC neurology · 2020Article
- The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.Frontiers in immunology · 2020Article
- Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.Frontiers in immunology · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo test the hypothesis that accelerated peripheral blood mononuclear cell recovery after alemtuzumab treatment of multiple sclerosis is associated with recurrent disease activity and to investigate the claim that CD4 counts greater than 388.5 × 10(6) cells/mL at 12 months can be used to identify patients who may benefit from further treatment.
methodsA total of 108 patients were followed for a median of 99 months post alemtuzumab. Patients were classified as active or nonactive after each cycle of treatment based on clinical relapse, increasing disability, or new T2/enhancing MRI lesions. These outcomes were correlated with CD4, CD8, CD19, CD56+ NK, and monocyte counts.
resultsOf 108 patients, 56 (52%) relapsed at some point during follow-up. Mean annualized relapse rate after alemtuzumab was 0.17 vs 1.67 prior to treatment (equating to a 90% reduction). Of 108 patients, 28 (26%) met the criteria for sustained accumulation of disability. Median time to the lower limit of normal for CD19, CD8, and CD4 was 3, 19.5, and 32 months, respectively. There was no significant difference in the recovery of any cell population between patients with and without disease activity or accumulation of disability after treatment.
conclusionThis study does not support the use of cell counts as biomarkers for identifying patients at greater risk of active disease following treatment with alemtuzumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.